Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 July 1.
Published in final edited form as:
PMCID: PMC3159729

Responding to the National HIV/AIDS Strategy – Setting the Research Agenda

The National HIV/AIDS Strategy (NHAS) has three goals: (1) reduce the number of people who become infected with HIV, (2) increase access to care and improve health outcomes of people living with HIV, and (3) reduce HIV-related health disparities. [1] In addition the plan and its implementation strategy call for achieving more coordination of HIV programs across the Federal government and between federal agencies and state, and local governments. [2] Accompanying the Strategy is an Implementation Plan that identifies the steps to be taken by Federal agencies as well as all parts of society to support the priorities outlined in the Strategy and sets target for the three goals to be achieved by 2015 (e.g. lowering the number of new HIV infections by 25%). [3] Herein we lay out a role for the National Institutes of Health in facilitating research that supports and informs the goals of the National HIV/AIDS Strategy.

Though the potential benefits of the National HIV Strategy for HIV-infected persons and the broader society are substantial, three important challenges must be addressed to effectively bring the strategy to scale in the United States. First, although virtually everyone who is HIV-infected is eventually identified, diagnosis often occurs too late in the disease to provide optimal benefit to the individual. In addition, until persons know they are infected, they are more likely to transmit their infection to others. Thus, it is critical to detect HIV-infected individuals earlier in their disease. Second, once HIV-infected individuals are identified, it is crucial that they quickly receive and then remain in care. Third, if the individual and society are to benefit from antiretroviral therapy, infected persons must receive and be adherent to treatment in order to maintain long-term virologic suppression to achieve better health outcomes and reduce HIV transmission rates.

While an emphasis on testing and treatment sounds primarily biomedical, the three challenges depend on behavioral, social, systems, and structural factors important to address in implementation of the NHAS. Early identification of HIV infection, especially for populations with greatest disease incidence, requires community- and provider-level interventions to make frequent HIV testing normative, easy to obtain, and free of stigma. Engaging and maintaining HIV-infected persons in care requires the development and implementation of practical interventions—at health care system, community, and individual levels—targeted toward those marginalized patient groups least likely to enter and remain without disruption in care. Well-maintained HIV virologic suppression, a cornerstone of treatment-as-prevention approaches, can be achieved only when patients likely to be nonadherent are identified and receive behavioral and social interventions to improve their long-term medication adherence.

Much is known about individual interventions that can achieve some of these goals, but we know much less about how to combine multiple approaches to have the greatest impact on a wide scale. Consensus among researchers is emerging on the need for “combination prevention,” by which we mean multilevel interventions that combine evidence-based individual social, behavioral, and biomedical approaches to produce a community-level impact on the HIV/AIDS epidemic. [4, 5] It is time to move beyond studying social, behavioral, and biomedical HIV prevention interventions in isolation and instead evaluate the impact of comprehensive, integrated, multilevel approaches implemented on a wide scale.

In this editorial, we will describe some current barriers to implementation of the National HIV/AIDS Strategy, present strategies to address them, and outline research needs relevant to the successful implementation of the Strategy.

Improving the Identification of Undiagnosed HIV Infection

The strategy has set as a target to increase the percentage of individuals who are aware of their HIV-infection from 79% to 905 by 2015. [3] To accomplish this target, social marketing campaigns designed to make knowledge of one's HIV status normative, such as Washington, DC's “Ask for the Test” campaign [6] and New York City's “Bronx Knows” campaign [7], have shown promise in decreasing the number of individuals unaware of their HIV infection. Research shows that community mobilization approaches have the potential to reach subpopulations at highest risk for HIV. [8] In addition, the CDC has recommended routine HIV testing in emergency departments, STD clinics, and other publicly funded settings for all patients where the patient population has an estimated HIV prevalence of 0.1% or greater. [9]

CDC recommendations call for persons at high risk—men who have sex with men (MSM), injection drug users and their sexual partners, sex workers, sexual partners of HIV-positive individuals, and heterosexuals with multiple partners—to be screened at least annually and for all people being treated for TB or STDs to receive HIV testing. More intensive routine screening programs are likely to be cost-effective only when focused on higher-risk populations, such as black MSM who represent 25% of the HIV epidemic, or in higher-risk settings. [10, 11] However, implementation of routine testing recommendations has proven challenging. In a recent study of six southeastern US community health centers that adopted routine point-of-care rapid testing, only 28% of patients were offered HIV tests, and fewer than 70% of those offered chose to have an HIV test. [12] Integrating appropriate HIV testing into private health-care settings is a crucial element to identifying undiagnosed HIV infections, yet very little research has been conducted in this area. Potential strategies for investigation in the private setting include interventions to increase provider HIV awareness and the use of HIV testing prompts within electronic medical record systems.

Identifying Individuals Earlier in Their Infection

In 2008 about one-third (32%) of individuals with an HIV diagnosis reported to CDC received an AIDS diagnosis within one year of their initial diagnosis. [13] Current approaches often identify HIV for the first time only late in the patient's HIV disease course. [13] This pattern is especially pronounced among marginalized populations and ethnic minorities, and leads to significant HIV health outcome disparities. Identifying individuals earlier in their HIV infection requires encouraging persons at high risk to test frequently. Research is needed to identify effective community mobilization strategies to facilitate frequent HIV testing, make regular testing normative, and decrease stigma associated with HIV and testing, especially for high-risk populations and under-tested minorities.

Specific interventions for low-income persons might include text messaging and low-value cash incentives to promote regular HIV testing. Making rapid HIV tests available to consumers in local pharmacies at a low cost is a strategy that could allow persons in high-risk groups to test their HIV status repeatedly over time, potentially increasing the identification of persons earlier in their course of disease. MSM at high risk for HIV increasingly use the Internet to meet new partners. A promising research intervention for these men is establishing the norm to include in personal profiles the date of last HIV testing; site banners that recommend HIV testing every three months for those at risk could be employed as well.

A second goal related to early HIV detection is to identify persons very soon after HIV infection, during the acute phase, a period characterized by high risk of HIV transmission to uninfected partners. [14] Identifying acutely HIV-infected persons could be aided by the use of newer HIV testing technologies (e.g., fourth-generation ELISA testing, combination antibody and antigen testing, or targeted nucleic acid testing of antibody-negative specimens). Research is needed to develop and evaluate acute HIV infection–awareness campaigns for the community and providers, emphasizing symptoms that often accompany primary infection and the increased infectiousness of acute HIV infection. [15] Research with a small sample of acutely HIV-infected persons has shown a reduction in transmission risk acts following notification of acute infection status, highlighting the potential to reduce onward HIV transmissions if acutely infected persons are made aware of their status and of their increased infectiousness. [16]

Unfortunately, policy does not always translate directly into action. Coordinated public health responses to acute/early HIV infection involving linkage to HIV care and facilitated partner counseling and referral services have been insufficiently studied. [17] A recent Institute of Medicine report identified many of the practical, policy, and regulatory barriers to the implementation of coordinated responses following the diagnosis of acute HIV infection. [18] Researchers must assess the most effective and efficient ways to overcome these barriers.

Linking and Retaining HIV-Infected Individuals in Care

The Strategy has established a target of increasing the proportion of newly diagnosed individuals who are linked to clinical within 3 months of their HIV diagnosis from 65% to 85%. In addition to linkage to routine care, it is important to respond to the distinct and separate challenge of retention in care. [19] Differing definitions and methods make measuring linkage to and retention in care difficult; however, we do know an estimated 30% to 50% of newly diagnosed HIV-infected individuals in the US fail to establish HIV care within six months. [20, 21] In addition, missed appointments are reported among 25% to 35% of HIV patients in care [2224], and estimates of retention in care (as measured by at least one visit every six months over a two-year period) range from 18% to 61%. [2527]

Engagement in care is vital for the treatment success of individual patients and for prevention at population levels. Care engagement is known to be worse in marginalized populations, resulting in significant health disparities. As with HIV detection and early identification goals, social marketing and community mobilization strategies aimed at making HIV treatment engagement normative need to be researched.

There is precedent for using linkage support services as core elements in medical care, especially for poor, ethnic-minority patients with cancer, [28] diabetes, [29] and other chronic diseases including HIV. [30] Early research showed the benefits of case management for linking HIV patients into care. [31, 32] More recently, patient navigator interventions have been found to reduce barriers in accessing care and to improve health outcomes for individuals with HIV in the US. [2830, 33] Navigators, who can be professionals or peers, assist HIV-infected individuals to make use of available resources and develop effective communication with providers, provide practical and emotional support (such as transportation or child care), escort patients, and help them understand the demands of HIV treatment. Patient navigators can be assigned to emergency departments and other health care settings including testing sites to facilitate linkage to care of HIV-infected persons, with the goal of ensuring initial care visits quickly after HIV detection.

Although navigator interventions have shown promise, there is considerable room for improvement in their implementation and in measuring their success. NHAS goals may be better served by defining “linkage success” as receiving an HIV care visit within one month of initial HIV diagnosis, rather than within three months as has been typical in research studies.

Retaining HIV-infected persons in care presents a significant challenge. Missed visits in the first year of care are associated with the risk of death and risk of mortality increases with the number of visits missed. [34] A study of HIV-infected persons in San Francisco showed an almost doubling of mean HIV viral load among those not engaged in care as compared to those in care. [35] Given its obvious importance, it is surprising that no randomized, controlled trials of interventions to retain HIV-infected persons in care have been conducted; and there is no consistent definition of what is meant by “in care” with respect to frequency or content of visits. In clinical trials testing drugs, cohort retention for study visits is a high priority, yet the strategies used to meet retention targets in trials have not been systematically applied to the challenge of keeping HIV patients in care. As with linkage to care, patient navigators could be used to track and assist patients—particularly those patients identified as being at high risk for attrition—to stay in care. Research attention to the development and testing of care retention interventions will benefit patients and benefit the field.

Maintaining Viral Suppression and Improving Health Outcomes

Treatment guidelines have gradually shifted toward beginning treatment at higher CD4 cell counts, with the goal of total HIV viral suppression. Recently, many clinicians have concluded that treatment should be recommended for all HIV-infected individuals, regardless of clinical status, at the time of diagnosis in order to improve long-term health outcomes. [36]

The NHAS aligns well with what the research community has described as a “test-and-treat” approach, which refers to the early identification of HIV and linking and retaining individuals in care with the goal of maintaining viral suppression. The test-and-treat strategy has the potential both to improve the health of HIV-infected individuals and to reduce new infections by reducing HIV-positive individuals' infectivity. [37] In contrast to the virtual eradication of HIV predicted by modeling of test-and-treat approaches in South Africa, modeling of the US epidemic suggests varying reductions in new HIV infections depending on the extent to which treatment and viral suppression are achieved in the community. [38] The goal of the NHAS is a 25% reduction in new infections in 5 years, which is within the range of modeled effects of increased testing and treatment in selected high-prevalence cities in the U.S. [35, 3945]

Improvement of health outcomes depends on behavioral factors associated with adherence to both treatment and care. Adherence interventions often involve practical tools such as pillboxes, reminders, and calendars. [46] When warranted, more intensive interventions to improve adherence include cognitive-behavioral approaches, social support, contingency management, home visits, and directly observed therapy. [4750]

Care for mental health and substance abuse plays a central role in improving health outcomes. Research has shown that substance abuse and depression are prevalent among HIV patients in care. [51, 52] Promising areas of research include short, computer-based screening for these conditions as well as adherence counseling in clinic waiting rooms. Through the use of electronic medical records systems, assessments could be used to generate prompts for clinicians to direct attention to issues of adherence, mental health, and substance use. Clinic-based screening procedures could also include an assessment of HIV transmission risk acts and readiness for behavior change. [53, 54] These assessments could lead to provider-based prevention messages tailored to the stages of change model, [55, 56] previously shown to be both effective [53] and cost-effective for HIV prevention in clinic settings. [57]

Assessing the Impact of Multilevel Interventions

Given the nature of the multilevel interventions needed to implement the NHAS, we must develop and realign our existing research and funding frameworks to evaluate the epidemic impact of these new interventions. Prior HIV/AIDS prevention research has most often examined either theoretically informed, individual-level interventions to promote behavior change or biomedical prevention approaches, usually in isolation from one another. [53, 54] The synergistic effects of multilevel HIV/AIDS prevention approach, combining both behavioral and biomedical methods, need to be evaluated at the community level.

Indeed, there is progress in this direction with multi-level intervention feasibility research being conducted by the HIV Prevention Trials Network (HPTN) in the Bronx, NY, and Washington, DC. [5] In addition, the CDC through its “Enhanced Comprehensive HIV Prevention Planning” program or ECHPP is supporting the implementation of the NHAS in the 12 US cities most affected by the HIV epidemic to assess how multiple interventions can be combined in the most cost effective and efficient manner in real-world settings. [5862] NIH researchers are involved in this effort, providing technical assistance to local health departments on evidenced-based intervention and community-level evaluation methods.

Recent developments in the use of public health surveillance data give researchers the potential to examine an aggregate biologic measure of HIV-1 viral load for particular geographic locations. [44] Community viral load can serve as a population-level biologic marker of HIV transmission risk and antiretroviral therapy–mediated virologic suppression. [35] This innovation represents a methodological advance for evaluating the success of intervention strategies aimed at achieving goals of the NHAS.

Implementation of multilevel interventions and evaluation of their epidemic impact present challenges to traditional research paradigms. Current methods and research funding emphasize randomized, controlled trials of efficacy over evaluation and effectiveness studies responding to implementation challenges, thereby limiting needed research. A possible solution would be for the National Institutes of Health to develop mechanisms focusing on the implementation gaps we have identified. Such an approach could strengthen the evidence base needed to achieve the practical goals outlined in the National HIV/AIDS Strategy. The public health and scientific fields will be well served by the integration of biomedical advances in HIV prevention with the behavioral, social, and structural interventions needed for implementation on a large scale.

Table 1
Intervention Research to Respond to Implementation Gaps and Identified for the National HIV/AIDS Strategy.


This work was in part supported by a grant from the Office of AIDS Research at the National Institutes of Health, to support consensus development among prevention science centers supported by the National Institute of Mental Health (NIMH). Additional support has been provided by a center grant funded by the NIMH (Center for AIDS Prevention Studies, University of California, San Francisco P30MH062246, Stephen F. Morin, PhD, PI; Center for AIDS Intervention Research, Medical College of Wisconsin P30MH52776, Jeffrey A. Kelly, PhD, PI; HIV Center for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University P30MH043520, Anke A. Ehrhardt, PhD, PI; Center for HIV Identification, Prevention & Treatment Services, University of California, Los Angeles P30MH058107, Mary Jane Rotheram-Borus, PhD, PI; and Center for Interdisciplinary Research on AIDS, Yale University P30MH062294, Paul D. Cleary, PhD, PI. The views in this commentary are those of the authors and do not necessarily reflect the views of the funding agencies.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Office of National AIDS Policy . National HIV/AIDS Strategy for the United States. White House; Washington, DC: 2010.
2. White House Office of National AIDS Policy . National HIV/AIDS Strategy: Federal Implementation Plan. 2010.
3. Millett GA, et al. A way forward: the National HIV/AIDS Strategy and reducing HIV incidence in the United States. J Acquir Immune Defic Syndr. 55(Suppl 2):S144–7. [PubMed]
4. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008;372(9639):669–84. [PMC free article] [PubMed]
5. Vermund SH, et al. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis. 50(Suppl 3):S149–55. [PMC free article] [PubMed]
6. Castel A, et al. CROI. San Francisco, CA: 2010. Monitoring the Impact of Expanded HIV Testing in the District of Columbia Using Population-based HIV/AIDS Surveillance Data.
7. Mantsios A, et al. Preliminary findings from a borough-wide initiative to scale up HIV screening in New York City. National HIV Prevention Conference; Atlanta. 2009.
8. Khumalo-Sakutukwa G, et al. Project Accept (HPTN 043): a community-based intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and Thailand. J Acquir Immune Defic Syndr. 2008;49(4):422–31. [PMC free article] [PubMed]
9. Branson BM, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17. quiz CE1–4. [PubMed]
10. Patel P, et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr. 2006;42(1):75–9. [PubMed]
11. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America--forgotten but not gone. N Engl J Med. 362(11):967–70. [PubMed]
12. Myers JJ, et al. Routine Rapid HIV Screening in Six Community Health Centers Serving Populations at Risk. J Gen Intern Med. 2009 [PMC free article] [PubMed]
13. CDC . HIV Surveillance Report. Volume 20. CDC; Atlanta: 2008. Diagnoses of HIV infection and AIDS in the United States and Dependent Areas, 2008.
14. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis. 2005;191(9):1391–3. [PubMed]
15. Remien RH, et al. Lack of understanding of acute HIV infection among newly-infected persons-implications for prevention and public health: The NIMH Multisite Acute HIV Infection Study: II. AIDS Behav. 2009;13(6):1046–53. [PMC free article] [PubMed]
16. Steward WT, et al. Behavior Change Following Diagnosis with Acute/Early HIV Infection-A Move to Serosorting with Other HIV-Infected Individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav. 2009 [PMC free article] [PubMed]
17. Kelly JA, et al. Lessons learned about behavioral science and acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: V. AIDS Behav. 2009;13(6):1068–74. [PMC free article] [PubMed]
18. Institute of Medicine . HIV Screening and Access to Care. Institute of Medicine of the National Academies; Washington, DC: 2010.
19. Mugavero MJ. Improving engagement in HIV care: what can we do? Top HIV Med. 2008;16(5):156–61. [PubMed]
20. Fleming PL, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV Prevalence in the United States, 2000. 9th Conference on Retroviruses and Opportunistic Infections; Seattle, WA. 2002.
21. Giordano TP, et al. Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care. 2005;17(6):773–83. [PubMed]
22. Catz S, et al. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care. 1999;11(3):361–73. [PubMed]
23. Israelski D, et al. Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. Prev Med. 2001;33(5):470–5. [PubMed]
24. McClure JB, Catz SL, Brantley PJ. Early Appointment Adherence Among Persons Living with HIV. AIDS and Behavior. 1999;3(2):157–165.
25. Sherer R, et al. HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care. AIDS Care. 2002;14(Suppl 1):S31–44. [PubMed]
26. Ashman JJ, Conviser R, Pounds MB. Associations between HIV-positive individuals' receipt of ancillary services and medical care receipt and retention. AIDS Care. 2002;14(Suppl 1):S109–18. [PubMed]
27. Lo W, MacGovern T, Bradford J. Association of ancillary services with primary care utilization and retention for patients with HIV/AIDS. AIDS Care. 2002;14(Suppl 1):S45–57. [PubMed]
28. Freeman HP, Muth BJ, Kerner JF. Expanding access to cancer screening and clinical follow-up among the medically underserved. Cancer Pract. 1995;3(1):19–30. [PubMed]
29. Gary TL, et al. A randomized controlled trial of the effects of nurse case manager and community health worker team interventions in urban African-Americans with type 2 diabetes. Control Clin Trials. 2004;25(1):53–66. [PubMed]
30. Kushel MB, et al. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis. 2006;43(2):234–42. [PubMed]
31. Gardner LI, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. Aids. 2005;19(4):423–31. [PubMed]
32. HIV/AIDS Bureau . Outreach: Engaging People in HIV Care. HRSA; Rockville, MD: 2006.
33. Bradford JB, Coleman S, Cunningham W. HIV System Navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS. 2007;21(Suppl 1):S49–58. [PubMed]
34. Giordano TP, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493–9. [PubMed]
35. Das M, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 5(6):e11068. [PMC free article] [PubMed]
36. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2011:1–174. Available at
37. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. Jama. 2009;301(22):2380–2. [PubMed]
38. Granich RM, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57. [PubMed]
39. Wagner BG, Kahn JS, Blower S. Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? Aids. 24(5):775–6. [PMC free article] [PubMed]
40. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. Aids. 24(5):729–35. [PMC free article] [PubMed]
41. Holtgrave DR. Potential and limitations of a 'test and treat' strategy as HIV prevention in the United States. Int J Clin Pract. 64(6):678–81. [PubMed]
42. Walensky RP, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 51(4):392–400. [PMC free article] [PubMed]
43. Charlebois ED, et al. The Effect of Expanded Antiretroviral Treatment Strategies on the HIV Epidemic among Men who have Sex with Men in San Francisco. Clinical Infectious Diseases. In press. [PMC free article] [PubMed]
44. Montaner JS, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 376(9740):532–9. [PMC free article] [PubMed]
45. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 153(12):778–89. [PMC free article] [PubMed]
46. Simoni JM, et al. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10(6):515–21. [PubMed]
47. Simoni JM, et al. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychol. 2007;26(4):488–95. [PubMed]
48. Antoni MH, et al. Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy. Psychosom Med. 2006;68(1):143–51. [PubMed]
49. Sorensen JL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007;88(1):54–63. [PMC free article] [PubMed]
50. Remien RH, et al. Couple-focused support to improve HIV medication adherence: a randomized controlled trial. Aids. 2005;19(8):807–14. [PubMed]
51. Bing EG, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8. [PubMed]
52. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158(5):725–30. [PubMed]
53. Grimley DM, et al. Provider-delivered, theory-based, individualized prevention interventions for HIV positive adults receiving HIV comprehensive care. AIDS Behav. 2007;11(5 Suppl):S39–47. [PubMed]
54. Koester KA, et al. Implementation of HIV prevention interventions with people living with HIV/AIDS in clinical settings: challenges and lessons learned. AIDS Behav. 2007;11(5 Suppl):S17–29. [PubMed]
55. Bachmann LH, et al. Risk behaviours in HIV-positive men who have sex with men participating in an intervention in a primary care setting. Int J STD AIDS. 2009;20(9):607–12. [PubMed]
56. Chen HT, et al. A process evaluation of the implementation of a computer-based, health provider-delivered HIV-prevention intervention for HIV-positive men who have sex with men in the primary care setting. AIDS Care. 2008;20(1):51–60. [PubMed]
57. Marseille E, et al. The Cost-Effectiveness of HIV Prevention Interventions for HIV-Infected Patients Seen in Clinical Settings. JAIDS. In press. [PubMed]
58. National Prevention Information Network Enhanced Comprehensive HIV Prevention Planning and Implementation for Metropolitan Statistical Areas Most Affected by HIV/AIDS: Phase II. 2011
59. McKleroy VS, et al. Adapting evidence-based behavioral interventions for new settings and target populations. AIDS Educ Prev. 2006;18(4 Suppl A):59–73. [PubMed]
60. Rotheram-Borus MJ, Klosinski LE, Etzel MA. Differences between proof-of-concept studies and effective implementation: routine, opt-out HIV testing in emergency departments. J Acquir Immune Defic Syndr. 2007;46(4):381–3. [PubMed]
61. Schackman BR. Implementation science for the prevention and treatment of HIV/AIDS. J Acquir Immune Defic Syndr. 55(Suppl 1):S27–31. [PMC free article] [PubMed]
62. Norton WE, et al. An agenda for advancing the science of implementation of evidence-based HIV prevention interventions. AIDS Behav. 2009;13(3):424–9. [PubMed]